GENPREX INC

GNPXNASDAQ

🏆 #5380 by market capUS Equity

$2.87▲ $0.09 (+3.05%)

Live

🔔

Track GNPX

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 3.0%

7d▼ 19.3%

14d▼ 17.3%

30d▼ 20.9%

ytd▼ 92.5%

1y▼ 98.4%

🏦Market Cap

$1M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $2.84 – $2.92
52-Week Range: $3.26 – $1,210.00
Volume: $1.78B
Avg Volume: $2.05B
Shares Outstanding: 504,934
Next Earnings: Nov 7, 2026

Fundamentals Snapshot

Annual Revenue: $161,018
Last Q Revenue: $37,776
P/E Ratio: -0.0
P/S Ratio: 0.0x
EPS (TTM): $-34.87
Dividend Yield: 0.00%
Dilution (1yr): +329.4%

Why Investors Own GNPX

✓High-growth profile — revenue up +50.3% YoY with expanding US Equity exposure.
✓Healthy economics — 31% gross margin and 15% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GENPREX INC

GNPX

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$16M▼ −26.7% YoY

Free Cash Flow

−$15M▼ −10.7% YoY

Shares Outstanding

42K▲ +329.4% YoY

Net Cash

$8M▲ +$6M YoY

StockOtter · stockotter.space

About GENPREX INC

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

🦦